These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 25475039

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
    Jackson GH, Morgan GJ, Davies FE, Wu P, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Boyd KD, Osborne WL, Cook G, Child JA.
    Br J Haematol; 2014 Jul; 166(1):109-17. PubMed ID: 24673708
    [Abstract] [Full Text] [Related]

  • 3. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA.
    J Clin Oncol; 2005 Dec 01; 23(34):8580-7. PubMed ID: 16314620
    [Abstract] [Full Text] [Related]

  • 4. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid.
    Olson KB, Hellie CM, Pienta KJ.
    Urology; 2005 Sep 01; 66(3):658. PubMed ID: 16140106
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel.
    Miyazaki H, Nishimatsu H, Kume H, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Ishikawa A, Igawa Y, Hirano Y, Homma Y.
    BJU Int; 2012 Dec 01; 110(11 Pt B):E520-5. PubMed ID: 22578070
    [Abstract] [Full Text] [Related]

  • 7. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
    Otto S, Schreyer C, Hafner S, Mast G, Ehrenfeld M, Stürzenbaum S, Pautke C.
    J Craniomaxillofac Surg; 2012 Jun 01; 40(4):303-9. PubMed ID: 21676622
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis.
    Tennis P, Rothman KJ, Bohn RL, Tan H, Zavras A, Laskarides C, Calingaert B, Anthony MS.
    Pharmacoepidemiol Drug Saf; 2012 Aug 01; 21(8):810-7. PubMed ID: 22711458
    [Abstract] [Full Text] [Related]

  • 11. Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients.
    Lescaille G, Coudert AE, Baaroun V, Ostertag A, Charpentier E, Javelot MJ, Tolédo R, Goudot P, Azérad J, Berdal A, Spano JP, Ruhin B, Descroix V.
    Bone; 2014 Jan 01; 58():103-7. PubMed ID: 24120382
    [Abstract] [Full Text] [Related]

  • 12. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies.
    Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinert S, Solomayer EF, Wallwiener D, Krimmel M.
    Gynecol Oncol; 2009 Mar 01; 112(3):605-9. PubMed ID: 19136147
    [Abstract] [Full Text] [Related]

  • 13. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
    Rodrigues P, Hering FO, Bruna P, Meller A, Afonso Y.
    Int J Urol; 2007 Apr 01; 14(4):317-20. PubMed ID: 17470161
    [Abstract] [Full Text] [Related]

  • 14. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
    Estilo CL, Van Poznak CH, Wiliams T, Bohle GC, Lwin PT, Zhou Q, Riedel ER, Carlson DL, Schoder H, Farooki A, Fornier M, Halpern JL, Tunick SJ, Huryn JM.
    Oncologist; 2008 Aug 01; 13(8):911-20. PubMed ID: 18695259
    [Abstract] [Full Text] [Related]

  • 15. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P.
    Clin Ther; 2007 Aug 01; 29(8):1548-58. PubMed ID: 17919538
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
    Denham JW, Wilcox C, Joseph D, Spry NA, Lamb DS, Tai KH, Matthews J, Atkinson C, Turner S, Christie D, Gogna NK, Kenny L, Duchesne G, Delahunt B, McElduff P.
    Lancet Oncol; 2012 Dec 01; 13(12):1260-70. PubMed ID: 23151431
    [Abstract] [Full Text] [Related]

  • 18. Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies.
    Assaf AT, Smeets R, Riecke B, Weise E, Gröbe A, Blessmann M, Steiner T, Wikner J, Friedrich RE, Heiland M, Hoelzle F, Gerhards F.
    Anticancer Res; 2013 Sep 01; 33(9):3917-24. PubMed ID: 24023329
    [Abstract] [Full Text] [Related]

  • 19. Intravenous bisphosphonate-related osteonecrosis of the jaw: long-term follow-up of 109 patients.
    Watters AL, Hansen HJ, Williams T, Chou JF, Riedel E, Halpern J, Tunick S, Bohle G, Huryn JM, Estilo CL.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Feb 01; 115(2):192-200. PubMed ID: 23036797
    [Abstract] [Full Text] [Related]

  • 20. Bisphosphonate-associated osteonecrosis of the jaw 2 years after teeth extractions: a case report solved with non-invasive treatment.
    Gómez-Moreno G, Arribas-Fernández MC, Fernández-Guerrero M, Boquete-Castro A, Aguilar-Salvatierra A, Guardia J, Botticelli D, Calvo-Guirado JL.
    Eur Rev Med Pharmacol Sci; 2014 Feb 01; 18(9):1391-7. PubMed ID: 24867519
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.